Clinical Trial Detail

NCT ID NCT02020070
Title Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate cancer

Therapies

Ipilimumab

Degarelix

Age Groups: adult

No variant requirements are available.